You are in the accessibility menu

Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerez Riera, Andres Ricardo-
dc.contributor.authorAbreu, Luiz Carlos de-
dc.contributor.authorValenti, Vitor Engrácia-
dc.contributor.authorFonseca, Fernando A. L.-
dc.contributor.authorFerreira, Marcelo-
dc.contributor.authorVanderlei, Luiz Carlos Marques-
dc.contributor.authorFerreira Filho, Celso-
dc.contributor.authorMonteiro, Carlos B. de Mello-
dc.contributor.authorRolim Neto, Modesto Leite-
dc.contributor.authorRodrigues, Luciano M. R.-
dc.contributor.authorFerreira, Celso-
dc.identifier.citationJournal of Clinical & Experimental Cardiology, v. 04, n. 4, p. 1, 2011.-
dc.description.abstractIvabradine (IVB) is a heart rate lowering agent that acts via selective inhibition of the pacemaker funny current in sinoatrial nodal P cells, thus, reducing heart rate at rest and during exercise with minimal effect on myocardial contractility, blood pressure, and intracardiac conduction. IVB exerts no effect on external respiratory function parameters and it may also play a role in patients with concurrent chronic obstructive pulmonary disease. This property constitutes an important advantage over β-blockers. IVB acts by reducing the heart rate in a mechanism different from β-blockers, calcium channel blockers or late sodium channel blockers, three commonly prescribed antianginal drugs. As clinical trials have shown, it is remarkably well-tolerated and offers an alternative for patients who cannot take β-blockers. The combination of IVB and atenolol at commonly used doses in patients with chronic stable angina produced additional efficacy with no untoward effect on safety or tolerability. Additionally, side effects are rare and largely limited to a luminous phenomenon or phosphenes. This sensation is thought to be due to a block of Ih in the retina, a current very similar to cardiac If channels. IVB is contraindicated in patients with sick sinus syndrome or sinus node dysfunction and in patients taking hepatic inhibitors of Cytochrome P450 family 3, subfamily A, polypeptide 4 (abbreviated CYP3A4), with exception of omeprazole or lansoprazole. This review briefly summarizes the main studies regarding this drug.en
dc.sourceCurrículo Lattes-
dc.titleIvabradine: Just another New Pharmacological Option for Heart Rate Control?en
dc.contributor.institutionFaculdade de Medicina do ABC (FMABC)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionFaculdade Federal do Ceará (UFC)-
dc.description.affiliationUnespDepartamento de Fisioterapia, Faculdade de Ciência e Tecnologia, UNESP, Presidente Prudente, SP, Brasil-
dc.rights.accessRightsAcesso aberto-
dc.relation.ispartofJournal of Clinical & Experimental Cardiology-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.